IN201741031902A - - Google Patents

Info

Publication number
IN201741031902A
IN201741031902A IN201741031902A IN201741031902A IN201741031902A IN 201741031902 A IN201741031902 A IN 201741031902A IN 201741031902 A IN201741031902 A IN 201741031902A IN 201741031902 A IN201741031902 A IN 201741031902A IN 201741031902 A IN201741031902 A IN 201741031902A
Authority
IN
India
Application number
IN201741031902A
Other languages
English (en)
Inventor
Thirumalai Rajan Srinivasan
Eswaraiah Sajja
Venkat Reddy Ghojala
Bekkam Markandeya
Original Assignee
Msn Laboratories Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msn Laboratories Private Ltd filed Critical Msn Laboratories Private Ltd
Priority to IN201741031902A priority Critical patent/IN201741031902A/en
Publication of IN201741031902A publication Critical patent/IN201741031902A/en

Links

IN201741031902A 2017-09-08 2017-09-08 IN201741031902A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN201741031902A IN201741031902A (zh) 2017-09-08 2017-09-08

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201741031902A IN201741031902A (zh) 2017-09-08 2017-09-08

Publications (1)

Publication Number Publication Date
IN201741031902A true IN201741031902A (zh) 2019-03-15

Family

ID=86850777

Family Applications (1)

Application Number Title Priority Date Filing Date
IN201741031902A IN201741031902A (zh) 2017-09-08 2017-09-08

Country Status (1)

Country Link
IN (1) IN201741031902A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480086A (zh) * 2020-12-23 2021-03-12 中山奕安泰医药科技有限公司 奥斯替尼的精制方法
CN115819406A (zh) * 2023-02-24 2023-03-21 淄博百极荣创医药科技有限公司 3-(4-嘧啶)-1h-吲哚类化合物的合成方法
WO2023194531A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Improved process for the manufacture of osimertinib

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112480086A (zh) * 2020-12-23 2021-03-12 中山奕安泰医药科技有限公司 奥斯替尼的精制方法
WO2023194531A1 (en) * 2022-04-07 2023-10-12 Astrazeneca Ab Improved process for the manufacture of osimertinib
CN115819406A (zh) * 2023-02-24 2023-03-21 淄博百极荣创医药科技有限公司 3-(4-嘧啶)-1h-吲哚类化合物的合成方法

Similar Documents

Publication Publication Date Title
BR122021024397A2 (zh)
BR122021023687A2 (zh)
BR122021000189A2 (zh)
BR122022025811B8 (zh)
BR112019008823A2 (zh)
BR112020006084A8 (zh)
BR122021014832A2 (zh)
BR202018014992U2 (zh)
BR122022003520A2 (zh)
BR112020008820A2 (zh)
BR202017025154U2 (zh)
BR102017023327A2 (zh)
BR202017021228U2 (zh)
BR202017020981U2 (zh)
BR202017017068U2 (zh)
BR202017016984U2 (zh)
BR202017016924U2 (zh)
BR102017015495A2 (zh)
BR102017015250A2 (zh)
BR102017014430A2 (zh)
BR202017012548U2 (zh)
BR202017011220U2 (zh)
BR202017010814U2 (zh)
BR202017010373U2 (zh)
BR202017009870U2 (zh)